Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy

Richard M. Novak, Li Chen, Rodger David MacArthur, John D. Baxter, Kathy Huppler Hullsiek, Grace Peng, Ying Xiang, Christopher Henely, Barry Schmetter, Jonathan Uy, Mary Van Den Berg-Wolf, Michael Kozal

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Background. The prevalence of drug resistance among persons with newly acquired human immunodeficiency virus (HIV) infection is well documented. However, it is unclear to what extent these mutations persist in chronically infected, treatment-naive patients. Methods. Prevalence of and factors associated with genotypic drug resistance were analyzed retrospectively in a subset of 491 chronically HIV-infected, antiretroviral-naive patients enrolled at 25 cities in the Terry Beirn Community Programs for Clinical Research on Acquired Immune Deficiency Syndrome (AIDS) Flexible Initial Retrovirus Suppressive Therapies trial during 1999-2001. Resistance was defined on the basis of the International AIDS Society 2003 definition, as well as the presence of additional mutations at codons 215 (C/D/E/S) and 69 (A/N/S) in the pol gene. Prevalence of mutations was estimated by use of techniques for stratified random samples. Logistic regression models were used to determine factors associated with resistance. Results. Among the 491 chronically HIV-infected patients (mean CD4 cell count, 269 cells/mm3; 31% of patients had a prior AIDS diagnosis), 57 (11.6%) had ≥1 resistance mutation, resulting in an estimated prevalence for the cohort of 10.8% (95% confidence interval [CI], 9.5%-12.1%). The prevalence was 8.8% if the 1181 mutation was excluded. By drug class, the estimated prevalence of mutations conferring resistance to nucleoside reverse-transcriptase inhibitors was 7.8%, and the prevalence was 3.0% for nonnucleoside reverse-transcriptase inhibitors and 0.7% for protease inhibitors. In a multiple logistic regression analysis, non-Hispanic white subjects were twice as likely than African American subjects to have resistance (odds ratio [OR], 2.1; 95% CI, 1.1-4.1; P = .03), and there was a 40% increase per year in prevalence of mutations by later year of enrollment (OR, 1.4; 95% CI, 1.0-2.1; P = .05). Conclusions. These results demonstrate the persistence of drug resistance mutations in chronically HIV-infected patients and an increasing prevalence of resistance over time, and they support genotyping of virus at baseline for chronically HIV-infected patients.

Original languageEnglish (US)
Pages (from-to)468-474
Number of pages7
JournalClinical Infectious Diseases
Volume40
Issue number3
DOIs
StatePublished - Feb 1 2005

Fingerprint

Drug Resistance
HIV
Mutation
Reverse Transcriptase Inhibitors
Therapeutics
Logistic Models
Confidence Intervals
Acquired Immunodeficiency Syndrome
Odds Ratio
pol Genes
Virus Diseases
Retroviridae
CD4 Lymphocyte Count
Protease Inhibitors
Nucleosides
Codon
African Americans
Regression Analysis
Viruses
Research

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients : Implications for routine resistance screening before initiation of antiretroviral therapy. / Novak, Richard M.; Chen, Li; MacArthur, Rodger David; Baxter, John D.; Hullsiek, Kathy Huppler; Peng, Grace; Xiang, Ying; Henely, Christopher; Schmetter, Barry; Uy, Jonathan; Van Den Berg-Wolf, Mary; Kozal, Michael.

In: Clinical Infectious Diseases, Vol. 40, No. 3, 01.02.2005, p. 468-474.

Research output: Contribution to journalArticle

Novak, Richard M. ; Chen, Li ; MacArthur, Rodger David ; Baxter, John D. ; Hullsiek, Kathy Huppler ; Peng, Grace ; Xiang, Ying ; Henely, Christopher ; Schmetter, Barry ; Uy, Jonathan ; Van Den Berg-Wolf, Mary ; Kozal, Michael. / Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients : Implications for routine resistance screening before initiation of antiretroviral therapy. In: Clinical Infectious Diseases. 2005 ; Vol. 40, No. 3. pp. 468-474.
@article{b87e96c7d855427183e87a3e5b956bca,
title = "Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy",
abstract = "Background. The prevalence of drug resistance among persons with newly acquired human immunodeficiency virus (HIV) infection is well documented. However, it is unclear to what extent these mutations persist in chronically infected, treatment-naive patients. Methods. Prevalence of and factors associated with genotypic drug resistance were analyzed retrospectively in a subset of 491 chronically HIV-infected, antiretroviral-naive patients enrolled at 25 cities in the Terry Beirn Community Programs for Clinical Research on Acquired Immune Deficiency Syndrome (AIDS) Flexible Initial Retrovirus Suppressive Therapies trial during 1999-2001. Resistance was defined on the basis of the International AIDS Society 2003 definition, as well as the presence of additional mutations at codons 215 (C/D/E/S) and 69 (A/N/S) in the pol gene. Prevalence of mutations was estimated by use of techniques for stratified random samples. Logistic regression models were used to determine factors associated with resistance. Results. Among the 491 chronically HIV-infected patients (mean CD4 cell count, 269 cells/mm3; 31{\%} of patients had a prior AIDS diagnosis), 57 (11.6{\%}) had ≥1 resistance mutation, resulting in an estimated prevalence for the cohort of 10.8{\%} (95{\%} confidence interval [CI], 9.5{\%}-12.1{\%}). The prevalence was 8.8{\%} if the 1181 mutation was excluded. By drug class, the estimated prevalence of mutations conferring resistance to nucleoside reverse-transcriptase inhibitors was 7.8{\%}, and the prevalence was 3.0{\%} for nonnucleoside reverse-transcriptase inhibitors and 0.7{\%} for protease inhibitors. In a multiple logistic regression analysis, non-Hispanic white subjects were twice as likely than African American subjects to have resistance (odds ratio [OR], 2.1; 95{\%} CI, 1.1-4.1; P = .03), and there was a 40{\%} increase per year in prevalence of mutations by later year of enrollment (OR, 1.4; 95{\%} CI, 1.0-2.1; P = .05). Conclusions. These results demonstrate the persistence of drug resistance mutations in chronically HIV-infected patients and an increasing prevalence of resistance over time, and they support genotyping of virus at baseline for chronically HIV-infected patients.",
author = "Novak, {Richard M.} and Li Chen and MacArthur, {Rodger David} and Baxter, {John D.} and Hullsiek, {Kathy Huppler} and Grace Peng and Ying Xiang and Christopher Henely and Barry Schmetter and Jonathan Uy and {Van Den Berg-Wolf}, Mary and Michael Kozal",
year = "2005",
month = "2",
day = "1",
doi = "10.1086/427212",
language = "English (US)",
volume = "40",
pages = "468--474",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients

T2 - Implications for routine resistance screening before initiation of antiretroviral therapy

AU - Novak, Richard M.

AU - Chen, Li

AU - MacArthur, Rodger David

AU - Baxter, John D.

AU - Hullsiek, Kathy Huppler

AU - Peng, Grace

AU - Xiang, Ying

AU - Henely, Christopher

AU - Schmetter, Barry

AU - Uy, Jonathan

AU - Van Den Berg-Wolf, Mary

AU - Kozal, Michael

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Background. The prevalence of drug resistance among persons with newly acquired human immunodeficiency virus (HIV) infection is well documented. However, it is unclear to what extent these mutations persist in chronically infected, treatment-naive patients. Methods. Prevalence of and factors associated with genotypic drug resistance were analyzed retrospectively in a subset of 491 chronically HIV-infected, antiretroviral-naive patients enrolled at 25 cities in the Terry Beirn Community Programs for Clinical Research on Acquired Immune Deficiency Syndrome (AIDS) Flexible Initial Retrovirus Suppressive Therapies trial during 1999-2001. Resistance was defined on the basis of the International AIDS Society 2003 definition, as well as the presence of additional mutations at codons 215 (C/D/E/S) and 69 (A/N/S) in the pol gene. Prevalence of mutations was estimated by use of techniques for stratified random samples. Logistic regression models were used to determine factors associated with resistance. Results. Among the 491 chronically HIV-infected patients (mean CD4 cell count, 269 cells/mm3; 31% of patients had a prior AIDS diagnosis), 57 (11.6%) had ≥1 resistance mutation, resulting in an estimated prevalence for the cohort of 10.8% (95% confidence interval [CI], 9.5%-12.1%). The prevalence was 8.8% if the 1181 mutation was excluded. By drug class, the estimated prevalence of mutations conferring resistance to nucleoside reverse-transcriptase inhibitors was 7.8%, and the prevalence was 3.0% for nonnucleoside reverse-transcriptase inhibitors and 0.7% for protease inhibitors. In a multiple logistic regression analysis, non-Hispanic white subjects were twice as likely than African American subjects to have resistance (odds ratio [OR], 2.1; 95% CI, 1.1-4.1; P = .03), and there was a 40% increase per year in prevalence of mutations by later year of enrollment (OR, 1.4; 95% CI, 1.0-2.1; P = .05). Conclusions. These results demonstrate the persistence of drug resistance mutations in chronically HIV-infected patients and an increasing prevalence of resistance over time, and they support genotyping of virus at baseline for chronically HIV-infected patients.

AB - Background. The prevalence of drug resistance among persons with newly acquired human immunodeficiency virus (HIV) infection is well documented. However, it is unclear to what extent these mutations persist in chronically infected, treatment-naive patients. Methods. Prevalence of and factors associated with genotypic drug resistance were analyzed retrospectively in a subset of 491 chronically HIV-infected, antiretroviral-naive patients enrolled at 25 cities in the Terry Beirn Community Programs for Clinical Research on Acquired Immune Deficiency Syndrome (AIDS) Flexible Initial Retrovirus Suppressive Therapies trial during 1999-2001. Resistance was defined on the basis of the International AIDS Society 2003 definition, as well as the presence of additional mutations at codons 215 (C/D/E/S) and 69 (A/N/S) in the pol gene. Prevalence of mutations was estimated by use of techniques for stratified random samples. Logistic regression models were used to determine factors associated with resistance. Results. Among the 491 chronically HIV-infected patients (mean CD4 cell count, 269 cells/mm3; 31% of patients had a prior AIDS diagnosis), 57 (11.6%) had ≥1 resistance mutation, resulting in an estimated prevalence for the cohort of 10.8% (95% confidence interval [CI], 9.5%-12.1%). The prevalence was 8.8% if the 1181 mutation was excluded. By drug class, the estimated prevalence of mutations conferring resistance to nucleoside reverse-transcriptase inhibitors was 7.8%, and the prevalence was 3.0% for nonnucleoside reverse-transcriptase inhibitors and 0.7% for protease inhibitors. In a multiple logistic regression analysis, non-Hispanic white subjects were twice as likely than African American subjects to have resistance (odds ratio [OR], 2.1; 95% CI, 1.1-4.1; P = .03), and there was a 40% increase per year in prevalence of mutations by later year of enrollment (OR, 1.4; 95% CI, 1.0-2.1; P = .05). Conclusions. These results demonstrate the persistence of drug resistance mutations in chronically HIV-infected patients and an increasing prevalence of resistance over time, and they support genotyping of virus at baseline for chronically HIV-infected patients.

UR - http://www.scopus.com/inward/record.url?scp=13444279867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444279867&partnerID=8YFLogxK

U2 - 10.1086/427212

DO - 10.1086/427212

M3 - Article

C2 - 15668873

AN - SCOPUS:13444279867

VL - 40

SP - 468

EP - 474

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -